An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]
Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904. The authors have advised there is an error in Figure 1C on page 2894. The key “OLZ/SAM” should read “Olanzapine + samidorphan 10 mg” and “Olanzapine&rdq...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2f956761b90540fb83ae4e6a7146f4e3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904.
The authors have advised there is an error in Figure 1C on page 2894. The key “OLZ/SAM” should read “Olanzapine + samidorphan 10 mg” and “Olanzapine” should read “Olanzapine + placebo”.
Figure 1 legend, the text “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12 in the combined OLZ/SAM groups (OLZ/SAM 5/10 mg, 10/10 mg, and 20/10 mg) versus olanzapine was the primary endpoint; only the olanzapine + placebo and olanzapine + samidorphan 10-mg groups are presented here to allow cross-study comparisons” should read “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12, was the primary endpoint comparing the combined olanzapine + samidorphan groups versus the olanzapine + placebo group; to allow cross-study comparisons, only the olanzapine + samidorphan 10-mg and the olanzapine + placebo groups are presented here”.
Read the original article |
|---|